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EDITORIAL
The Holy Grail: Pathological indices in lupus nephritis
Interpretation of renal biopsies from patients with sys- gist to examine in detail each individual histologic fea-
temic lupus erythematosus (SLE) is complicated by the ture,” and they developed a scoring system and lists of
marked variability of the pathology. The nature and the “active” (potentially reversible acute inflammation) and
distribution of the glomerular lesions vary among pa- “inactive” (irreversible scars) lesions [5]. In subsequent
tients, among the glomeruli within a biopsy, and even analyses, indices of renal pathology were created from
within individual glomeruli. SLE is a chronic disease, the semiquantitative scores, and the activity (AI) and
and the glomeruli often show both acute inflammation chronicity (CI) indices developed by Austin et al are the
and scarring. In addition, SLE tubulointerstitial and vas- most widely accepted and influential [6, 7]. However,
cular pathology may accompany the glomerular lesions. histological indices have been criticized because the AI
Despite the many pathological permutations, the very does not predict outcome, and study of the CI yields
first renal biopsy study in patients with SLE demonstrated mixed results, with some investigators finding them prog-
that outcome was a function of the extent of glomerular nostically useful while others find that they do not predict
inflammation [1]. Confirmation of this seminal observa- outcomes [reviewed in 8]. Although they are unable to
tion and the contributions of many nephrologists and define a score that has the sensitivity and specificity to
renal pathologists culminated in the World Health Orga- reliably identify patients who will subsequently develop
nization (WHO) Classification of SLE Glomerulonephri- progressive renal disease [3], the AI and CI may find
tis in 1982 [2]. The WHO classification is easily learned, application as pathological summaries [6, 7].
readily performed and reproducible, and it has become In the current issue of Kidney International, Hill et al
the standard method by which the pathologist communi- attempt to improve upon the information revealed by a
cates the extent and severity of glomerular pathology to renal biopsy of SLE nephritis by utilizing a more detailed
the nephrologist. Because the prognosis is related to the histological analysis [9]. Their model comprises the sum
WHO Class of glomerular disease [3], the renal biopsy of four indices: the glomerular activity index, modified
serves as a guide for the clinician concerned with therapy from the AI of Austin et al [6, 7] adds the presence
for the SLE patient with renal involvement [4]. of glomerular monocytes while eliminating interstitial
Despite its success in defining the classes of glomerular inflammation; the tubulointerstitial activity index includes
disease that require therapy, the WHO Classification does histological signs of tubular injury and interstitial inflam-
not identify which patients with segmental glomerulone- mation but excludes tubular atrophy; the chronic lesions
phritis, diffuse glomerulonephritis, and mixed membra- index, modified from the CI of Austin et al [6, 7], includes
nous and proliferative lesions will develop progressive both glomerular sclerosis and tubular atrophy; and the
renal disease. Admittedly, the simplicity of the WHO immunofluorescence index is based on semiquantitation
Classification ignores the individual histological compo- of immunofluorescence staining. In developing the index
nents of the acute inflammatory lesion, does not quanti- the authors demonstrated correlations among the mor-
tate the extent of glomerular inflammation and scarring, phological features, the component indices, and the clini-
does not separately categorize lesions which are more cal parameters that imply that the assignment of the
characteristic of a protracted clinical course, and does histological elements to the component indices is valid
not include tubulointerstitial and vascular pathology. It and that the indices reflect the underlying pathogenetic
has been suggested that a more inclusive and quantitative mechanism. In addition, significant correlations were ob-
pathological analysis might improve the prognostic served between the biopsy index and the clinical parame-
power of the renal biopsy. Conrad Pirani, the renal pa- ters at the time of the initial biopsy and at the protocol
thologist for many of the early, influential clinicopatho- biopsy performed six months later, and these correla-
logical studies of lupus nephritis, and his clinician col- tions were higher than for the predecessor indices. The
leagues [1, 5] developed a semiquantitative method for study also sought to optimize correlations between the
analyzing renal biopsies because “it compels the patholo- biopsy index and study outcomes at the time of the initial
biopsy and in biopsies following treatment. Although
weak correlations were observed between the biopsyKey words: glomerular lesion, classification of lupus, systemic lupus
nephritis, inflammation, renal scarring. index and the study outcomes at the time of the first
biopsy, at the protocol biopsy performed after treatment,Ó 2000 by the International Society of Nephrology
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correlations between the biopsy index and the final se- with lupus nephritis has a suboptimal response to ther-
apy. As new approaches are developed, morphologicrum creatinine, end-stage renal disease, and doubling of
methods, such as the index proposed by Hill et al [9] thatthe serum creatinine were statistically significant and
focus on reversible pathology and specific pathogenicmuch stronger than before. Despite the apparent im-
mechanisms, may be helpful in evaluating therapeuticprovement, the correlations between the biopsy index
efficacy. One must concur with the authors that “theand outcome and the predecessor indices and outcome
greatest value of the new biopsy index will lie in thewere not significantly different. It is apparent that the
systematic evaluation of entire series of patients” and notWHO Classification does not utilize all available infor-
in the identification of individuals at risk of adverse out-mation in the renal biopsy, but the present study demon-
comes.strates that a detailed pathological analysis, using all
available morphological data, does not improve upon
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